AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This C$820M investment ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Tom Keith-Roach, President of AstraZeneca UK, commented, “This is fantastic news for lung cancer patients. These NICE decisions represent another step towards our bold ambition to eliminate cancer as ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Shares of AstraZeneca PLC AZN inched up 0.05% to £110.46 Thursday, on what proved to be an all-around positive trading ...

Shares of AstraZeneca PLC AZN inched up 0.04% to £110.50 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.73% to 8,502.35.

London, UK, Wednesday 22 January 2025 – AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the ...

AstraZeneca PLC AZN-Q is investing $820-million and creating more than 700 jobs in Ontario’s life sciences industry, stimulating growth within a national research and development sector that has ...